Mink Therapeutics Inc INKT

US Biotechnology

$10.23 ▼ -0.63% ($-0.07)

⬇️ Below Yest. Low ⚡ High Volume 🎈 Low Float 📅 Earnings This Week

Open $10.07

Prev Close $10.30

Day Range $10.00 – $10.51

52W Range $8.48 – $16.93

Market Cap $52.54M

Beta 0.65

EPS (TTM) $-2.40

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2021-10-15
Shares Out.	5,100,000
Website	minktherapeutics.com ↗
Phone	13026587581
Employees	15
Revenue	$0
Gross Profit	$0
Net Income	-$3.1M
Free Cash Flow	-$6.8M
Total Assets	$9.6M
Total Liabilities	$23.6M
Equity	-$14.0M

About Mink Therapeutics Inc

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.

Mink Therapeutics Inc is a publicly traded company under the ticker symbol INKT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.